Osimertinib versus platinum–pemetrexed for patients with...

  • Main
  • 2020 / 8
  • Osimertinib versus platinum–pemetrexed for patients with...
Annals of Oncology 2020 / 8

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Papadimitrakopoulou, V.A., Mok, T.S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebas
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.2100
Date:
August, 2020
File:
PDF, 486 KB
2020
Conversion to is in progress
Conversion to is failed